01093 CSPC PHARMA
Closed Add to PorfolioKey Financial Ratio (Fiscal Year: 12/2023) | |||
Current | 2.63X | Oper Margin | 23.8% |
---|---|---|---|
LT Debt/Equity | 0.3% | Net Margin | 18.7% |
Total Debt/Equity | 2.1% | Return on Equity | 17.7% |
Price/Book | 2.00X | Return on Assets | 12.7% |
(HKD 6.150) | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
Net Profit (MHKD) | 6,473.58 | 6,829.67 | 6,855.70 | 6,123.48 | 4,152.00 |
---|---|---|---|---|---|
Net Profit Growth (%) | -5.2 | -0.4 | +12.0 | +47.5 | +18.4 |
Earnings Per Share (HKD) | 0.545 | 0.573 | 0.574 | 0.512 | 0.347 |
Earnings Per Share Growth (%) | -4.9 | -0.1 | +12.0 | +47.5 | +18.7 |
Dividend Per Share (HKD) | 0.280 | 0.210 | 0.180 | 0.128 | 0.104 |
P/E* (X) | 11.28 | 10.73 | 10.72 | 12.01 | 17.71 |
Yield (%) | 4.55 | 3.41 | 2.93 | 2.07 | 1.69 |
Dividend Share (%) | 51.35 | 36.64 | 31.39 | 24.89 | 30.00 |
Book NAV (HKD) | 3.075 | 2.837 | 2.660 | 2.214 | 1.724 |
Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2024-03-28 21:40:23
Latest Result
(RMBMn) | 2023-12 | 2022-12 | Chg* (%) | 2021-12 |
Cover Period (mths) | 12 | 12 | NA | 12 |
---|---|---|---|---|
Turnover | 31,450 | 30,937 | +1.7 | 27,867 |
Operating Result | 7,411 | 7,550 | -1.8 | 6,787 |
Associates | -54.196 | -15.395 | +252.0 | 22.443 |
Profit Before Taxation | 7,389 | 7,582 | -2.5 | 6,847 |
Taxation | 1,317 | 1,350 | -2.4 | 1,159 |
Profit /( Loss) After Taxation | 6,073 | 6,232 | -2.6 | 5,688 |
Minority Interests | 199.368 | 140.66 | +41.7 | 82.939 |
Net Profit | 5,873 | 6,091 | -3.6 | 5,605 |
Earnings Per Share () | 0.5453 | 0.5731 | -4.9 | 0.5735 |
Dividend Per Share () | 0.2800 | 0.2100 | +33.3 | 0.1800 |
Announcement Date | 2024-03-20 | 2023-03-22 | NA | 2022-03-22 |
* Annualised
Last Update Time: 2024-03-28 21:40:28